Good news, bad news for Impax

The FDA has given tentative approval for an ANDA for a generic version of Eli Lilly's Cymbalta, a drug that treats depression and general anxiety. At the heart of the new drug is Impax Laboratories' drug delivery technology, a Hayward, CA-based company that specializes in controlled release for generics. reports that Cymbalta saw $3 billion in U.S. sales this past year. That was the good news for Impax. The bad news is that it is being sued by a unit of Johnson & Johnson over alleged patent infringement in its attempt to market a generic version of the ADHD drug Concerta. Generic Cymbalta report |  Generic Concerta news